Production & Sales

Clinigen to acquire US rights to Novartis cancer drug Proleukin

UK-based Clinigen Group has agreed to acquire the US rights to Proleukin (aldesleukin, human recombinant interleukin-2) from Novartis in an all-cash deal worth up to $210m.

World’s largest pharmaceutical firm selects ValGenesis to standardize corporate validation process enterprise-level

ValGenesis has announced that one of the world's largest, top rated life science companies has chosen to implement its 100% paperless Validation Lifecycle Management System (VLMS) across all its global sites to manage the corporate validation lifecycle process.

Mayne Pharma launches Lexette (halobetasol propionate) foam 0.05% in US

Mayne Pharma Group, a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, has launched LEXETTE (halobetasol propionate) Foam 0.05% in the US.

Neuraxpharm acquires CNS specialty pharma company Farmax

Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), has announced the acquisition of Farmax, a CNS specialty pharmaceutical company, from SVUS Pharma.

Hitachi Chemical to acquire apceth Biopharma

apceth Biopharma, a contract manufacturing organization in the field of cell and gene therapy, announced that Hitachi Chemical Co., Ltd. will enter into an agreement to acquire all shares of apceth Biopharma.

NextPharma to acquire Santen’s Tampere manufacturing facility

NextPharma, a European pharmaceutical contract development and manufacturing organization (CDMO), has agreed to acquire Santen’s Tampere manufacturing facility and associated operations.

Sobi acquires Synagis US rights from AstraZeneca

Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of US rights of Synagis (palivizumab) from AstraZeneca in a deal valued at around $1.6bn.

Circassia to buy US, China marketing rights to AIT’s AirNOvent

Circassia Pharmaceuticals has agreed to acquire the exclusive commercialization rights of AIT Therapeutics’ ventilator compatible nitric oxide product AirNOvent in the US and China.

BioNTech to acquire MAB Discovery’s antibody generation unit

BioNTech, a biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB Discovery, a unique player in the generation and development of sophisticated and therapeutically relevant monoclonal antibodies (mAbs), have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.